Compare Gogoro Inc (GGR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Moderna, Inc. — how do they compare? Gogoro Inc trades at $3.15 (market cap $56.21M), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 1399.2× Gogoro Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Moderna, Inc. for 59 Days on average.
| GGR | MRNA | |
|---|---|---|
Market Cap | $56.21M | $78.65B |
Volume | 14,026 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $203.46 |
52-Week Low | $2.20 | $22.36 |
Typical Hold Time | 14 Days | 59 Days |
Enterprise Value | $342.65M | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gogoro (GGR) trades at $3.15, up 5.35% today, but faces bearish technical signals and weak profitability, with a net loss of $79.97M in 2025. Revenue grew modestly to $281.48M, yet margins remain negative. Recent news highlights board changes and a $61.8M equity investment, signaling internal restructuring efforts. The stock shows oversold conditions with an RSI of 27.68, but moving averages indicate a downtrend.
The outlook is cautious due to persistent losses and high debt-to-asset ratio of 60%, though low valuation ratios (P/S 0.16, P/B 0.5) may attract value investors. Risks include execution challenges and competitive pressures. Analysts are neutral with 100% hold ratings, reflecting uncertainty about near-term turnaround.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
